On 30 March, Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease and Parkinson’s disease, announced preliminary findings from its experimental drug ANAVEX2-73 in people with Parkinson’s disease dementia (PDD). The open-label extension ANAVEX2-73-PDD-EP-001 Phase II study assessed safety, tolerability and efficacy of oral capsules of ANAVEX2-73 in people with PDD. This 48-week extension study was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001 Phase II study. Preliminary analysis reveals that ANAVEX2-73 was found to be generally safe and well tolerated. Safety findings in this study are consistent with the known safety profile of ANAVEX2-73. The study successfully achieved both primary and secondary objectives and demonstrated improvements of all efficacy endpoints over 48 weeks.
